AnaptysBio Inc.’s shares rose to a six-month high on Tuesday following the announcement of successful Phase 2b results from ...

The changes in drug therapy from 2003 to 2010 ... Recent changes in both treatments and outcomes of rheumatoid arthritis (RA) in Japan were analyzed by viewing the 'National Database of Rheumatic ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

In February 2025, A naptysBio announced promising results from a global Phase IIb trial (RENOIR) for rosnilimab, a novel ...

AnaptysBio (ANAB) stock gains as H.C. Wainwright upgrades the stock on promising Phase 2b trial data for its rheumatoid ...

AnaptysBio announces positive results from phase 2b trial of rosnilimab to treat rheumatoid arthritis: San Diego Thursday, June 5, 2025, 18:00 Hrs [IST] AnaptysBio, Inc., a clinic ...

Women with rheumatoid arthritis have a longer disease duration before being prescribed disease-modifying antirheumatic drugs ...

A large-scale study reveals that rheumatoid arthritis patients—especially those seropositive or on DMARD therapy—face ...

A commonly used arthritis medication failed to improve symptoms in people with a specific form of knee osteoarthritis, according to an article published June 2 in JAMA Internal Medicine. In a ...

The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...